Newsroom | 4042 results

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, con...

BOSTON--(BUSINESS WIRE)--EY US Announces Nabiha Saklayen of Cellino as an Entrepreneur Of The Year® 2025 New England Award Winner...

SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of tools and services for cell product development, today announced the launch of their first-of-its-kind PluriForm™ Organoid Kit, a turnkey solution to eliminate critical bottlenecks in organoid research and allow scientists to rapidly and reliably make pluripotent aggregates using quality-assured, induced pluripotent stem cells (iPSCs). The kit saves weeks of cell culture work and eliminates variability in organoid manufacturing, allowin...

SAN DIEGO--(BUSINESS WIRE)--iXCells Biotechnologies USA, Inc. (“iXCells”), a leading cell technology company specializing in the generation of predictive human disease models is pleased to announce the launch of its modular iPSCore™ platform. iXCells’ mission is to empower life science researchers and patient foundations to advance personalized therapies and accelerate discovery of better medicines for a healthier future. iXCells’ cell engineering platform iPSCore™ is a unified and dedicated sy...

MINNEAPOLIS--(BUSINESS WIRE)--Nu-Tek BioSciences, the market leader in high-performance, animal-origin-free (AOF) yeast extracts and peptones for the biopharmaceutical industry, today announced its participation in the BIO International Convention 2025. The premier global event for biotechnology, innovation, and collaboration will take place from June 16-19, 2025, in Boston, MA. Nu-Tek BioSciences will be a key representative at Booth 453 as part of the Minnesota Delegation via the Minnesota De...

SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing a poster presentation at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress, taking place in Barcelona on June 11-14, 2025. Details of the presentations are as follows: Poster Presentation Details: Title: “REGULATE-RA: A Phase 1 Stud...

ROCHESTER, Minn.--(BUSINESS WIRE)--Rion Aesthetics, an internationally recognized regenerative aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug (IND) application to proceed for a Phase 1 investigator-initiated trial evaluating Purified Exosome Product™ (PEP™) injected into the dermis. The study is sponsored and independently conducted by Clinical Testing Center of Beverly Hills and is being led by Dr. John H. Joseph, a...

VANCOUVER (Columbia Británica) y CAMBRIDGE (Inglaterra)--(BUSINESS WIRE)--STEMCELL Technologies, la mayor empresa de biotecnología de Canadá, tiene el placer de anunciar la adquisición de Cellular Highways Ltd a TTP Group Ltd. Cellular Highways es una empresa biotecnológica con sede cerca de Cambridge, Reino Unido, especializada en tecnologías avanzadas de clasificación celular con aplicaciones en terapia celular y génica, descubrimiento de fármacos e investigación celular en general, especialm...

VANCOUVER, British Columbia e CAMBRIDGE, Inghilterra--(BUSINESS WIRE)--STEMCELL Technologies, la più grande azienda canadese di biotecnologia, è lieta di annunciare l'acquisizione di Cellular Highways Ltd da TTP Group Ltd. Cellular Highways è una società di biotecnologia con sede vicino a Cambridge, Regno Unito, specializzata in tecnologie avanzate di selezione cellulare con applicazioni in terapia cellulare e genetica, scoperta di farmaci e ricerca cellulare in generale, soprattutto dove le ce...

VANCOUVER (Colombie-Britannique), et CAMBRIDGE (Angleterre)--(BUSINESS WIRE)--STEMCELL Technologies, la plus grande entreprise canadienne de biotechnologie, a le plaisir d’annoncer l’acquisition de Cellular Highways Ltd auprès de TTP Group Ltd. Basée près de Cambridge (Royaume-Uni), Cellular Highways est une société de biotechnologie spécialisée dans les technologies avancées de tri cellulaire applicables aux thérapies cellulaire et génique, à la découverte de médicaments et à la recherche cell...